What new developments have the participating companies such as Amgen brought to the 40th JPM Healthcare Conference?

The 40th JPM Healthcare Conference entered the second day.

Amgen and Arrakis Collaborate to Develop Innovative Small Molecule RNA Degraders

Amgen and Arrakis Therapeutics announced a research and development agreement to jointly discover and develop RNA degraders for difficult-to-drug targets in multiple therapeutic areas

▲Arrakis CEO Dr.

Mirati files new drug application for KRAS G12C inhibitor to US FDA

Mirati's executives announced at the JPM conference report that the company has completed the submission of its KRAS G12C inhibitor adagrasib to the US FDA at the end of last year.

Image source: Mirati's official website

Mirati expects to report efficacy durability data for adagrasib and efficacy data in patients with brain metastases this year

Targeting BCMA and CD22, Sana has reached two cell therapy R&D collaborations

One of Sana Biotechnology's goals is to develop in vivo and in vitro engineered cell therapies

In addition, the company today announced an agreement with the National Cancer Institute (NCI) to obtain a CD22-targeting CAR construct it has developed for in vivo gene therapy and in vitro allogeneic CAR-T therapy for the treatment of B-cell malignancies.

Received US$290 million investment from Roche, Xinrui accelerates the promotion of multi-omics early cancer detection platform

Freenome has announced that it has secured a $290 million investment from Roche, bringing the company's total funding to more than $1.

The company's blood test for early detection of colorectal cancer is currently being tested in a registrational clinical study

DMD gene therapy significantly improves motor function in patients

Sarepta Therapeutics announced updated clinical trial data on its investigational gene therapy SRP-9001 for the treatment of Duchenne muscular dystrophy (DMD) in a JPM report

SRP-9001 is a gene therapy that utilizes AAV viral vectors to express the dystrophin transgene

Roche and Sarepta reached a $2.

Using microRNA to silence multiple genes, Allogene collaborates to develop next-generation ready-to-use CAR-T cell therapy

Allogene announced yesterday that the US FDA has cleared all of the company's ready-to-use cell therapy clinical trials

While allogeneic CAR-T therapy introduces a CAR targeting tumor antigens, it also requires a series of modifications to T cells derived from healthy donors, such as inhibiting the expression of endogenous T cell receptors and reducing the patient's ability to respond to foreign substances.

▲Illustration of miCAR technology platform (Image source: Antion Biosciences official website)

References:

[1] JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage touts double-duty anxiety drug.

[2] Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics.

[3] Mirati Therapeutics corporate presentation.
Retrieved January 11, 2022, from https://s27.
q4cdn.
com/140416303/files/doc_presentation/2022/Mirati_Corporate-Presentation_10Jan2022_vFINAL.
pdf

[4] Significant Investment Accelerates Freenome's Multiomics Platform for the Early Detection of Cancer.
Retrieved January 11, 2022, from https:// -the-early-detection-of-cancer-301457689.
html

[5] Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular Dystrophy.
Retrieved January 11, 2022, from https ://investorrelations.
sarepta.
com/news-releases/news-release-details/sarepta-therapeutics-gene-therapy-srp-9001-shows-statistically

[6] Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology.
Retrieved January 11, 2022, from https://ir.
allogene.
com/news-releases/news-release-details/allogene- therapeutics-announces-exclusive-collaboration-and

(Original abridged)